Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Savara Inc SVRA

Healthcare Biotechnology
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SVRA)

Savara Announces New Employment Inducement Grant

Business Wire 3 days ago

Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024

Business Wire 3 days ago

Savara Announces Participation in Upcoming Healthcare Conferences

Business Wire 12 days ago

Savara Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire 13 days ago

Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Business Wire November 4, 2024

Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV

Business Wire October 22, 2024

Savara Announces New Employment Inducement Grant

Business Wire October 18, 2024

Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting

Business Wire October 1, 2024

Savara Announces New Employment Inducement Grant

Business Wire September 27, 2024
View More News ››

Opinion & Analysis (NDAQ:SVRA)

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Streetwise Reports January 2, 2020
View More Opinion ››

Bullboard Posts (NDAQ:SVRA)

Savara Announces Participation in Upcoming Healthcare Confer

JUST IN: $SVRA Savara Announces Participation in Upcoming Healthcare ConferencesSavara Inc. (Nasdaq: SVRA ) (the Company), a clinical...
whytestocks - 12 days ago

Savara to Host Analyst and Investor Webinar on September 30,

News; $SVRA Savara to Host Analyst and Investor Webinar on September 30, 2024Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage...
whytestocks - September 23, 2024

Savara Announces Pricing of $100.0 Million Underwritten Offe

BREAKING NEWS: $SVRA Savara Announces Pricing of $100.0 Million Underwritten Offering of Common StockSavara Inc. (Nasdaq: SVRA), a...
whytestocks - June 28, 2024

it's a buy today for me

at $3.37 per share,it looks like a this one will make a comeback and it was on my watchlist,so glta.
coolfooldumbguy - December 30, 2019

the bottom is past for

this one, I was really out of it today,so glta as I will try to stay sober for the rest of the week.
coolfooldumbguy - June 19, 2019

watching this one for

an entry point,so glta.
coolfooldumbguy - June 18, 2019
View more Bullboard ››

AJA Health and Wellness Inc.

AJA Health and Wellness Inc.

AJA Health and Wellness Inc. is focused on health and wellness solutions. The Company is engaged in operating a telemedicine ...
View More »